Sep 16, 2024
Dr. Monica Perez, the Scientific Chair at the Arms and Hands Lab at the Shirley Ryan AbilityLab and Professor of Physical Medicine and Rehabilitation at Northwestern University, is focused on developing drugs and strategies for treating those with spinal cord injuries. With no FDA-approved treatment, the current...
Sep 16, 2024
Dr. Monica Perez, the Scientific Chair at the Arms and Hands Lab at the Shirley Ryan AbilityLab and Professor of Physical Medicine and Rehabilitation at Northwestern University, is focused on developing drugs and strategies for treating those with spinal cord injuries. With no FDA-approved treatment, the current...
Jul 17, 2024
Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain....
Jul 17, 2024
Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain....
Jun 28, 2024
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to...